This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Steven Wolk, PhD
Vice President of Chemistry & Boulder Site Head at Editas Medicine
Speaker

Profile

Steve is currently the Vice President, Chemistry & Site Head, Boulder at Editas medicine. His team is responsibilities for characterization of guide RNAs (gRNAs) and ribonucleoprotein complexes (RNPs), which includes analytical method development, QC and stability testing, and biophysical characterization (e.g., thermodynamics, affinities and off-rates). He received his bachelor’s degree in Chemistry from UC San Diego, where he received the Harold Urey Award. He received his Ph.D. in Biophysical Chemistry from UC Berkeley, under Dr. Ignacio Tinoco, where he used 2D-NMR and other spectroscopic techniques to characterize nonstandard DNA structures. He has also led analytical groups at several other biotechnology companies (NexStar, Invenux, Amgen, SomaLogic), and has a broad background in analytical techniques used for the characterization of biomolecules.

Agenda Sessions

  • Analytical Challenges in the Characterization of CRISPR Therapeutics

    2:05pm